FY2025 EPS Estimates for Repligen Boosted by William Blair

Repligen Co. (NASDAQ:RGEN) – Equities research analysts at William Blair upped their FY2025 earnings per share estimates for Repligen in a research note issued on Wednesday, April 30th. William Blair analyst M. Larew now forecasts that the biotechnology company will post earnings per share of $1.68 for the year, up from their previous forecast of $1.67. The consensus estimate for Repligen’s current full-year earnings is $1.72 per share. William Blair also issued estimates for Repligen’s Q3 2026 earnings at $0.58 EPS and FY2026 earnings at $2.28 EPS.

Several other equities research analysts also recently issued reports on RGEN. StockNews.com upgraded Repligen from a “sell” rating to a “hold” rating in a report on Monday, April 28th. TD Cowen assumed coverage on shares of Repligen in a research report on Monday, February 10th. They set a “buy” rating and a $200.00 price target on the stock. Royal Bank of Canada cut their target price on shares of Repligen from $202.00 to $189.00 and set an “outperform” rating on the stock in a research note on Wednesday. HC Wainwright reissued a “buy” rating and issued a $180.00 price target on shares of Repligen in a research report on Friday, February 21st. Finally, Wolfe Research raised Repligen from a “peer perform” rating to an “outperform” rating and set a $160.00 price objective on the stock in a research report on Tuesday. Six analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $173.25.

Repligen Stock Performance

NASDAQ RGEN opened at $141.51 on Friday. The stock has a fifty day simple moving average of $137.82 and a 200-day simple moving average of $145.81. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The stock has a market cap of $7.95 billion, a PE ratio of -277.47, a P/E/G ratio of 4.54 and a beta of 1.27. Repligen has a twelve month low of $102.97 and a twelve month high of $182.52.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.35 by $0.04. The business had revenue of $169.17 million during the quarter, compared to analyst estimates of $163.65 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The business’s revenue was up 10.4% compared to the same quarter last year. During the same period in the prior year, the business earned $0.28 earnings per share.

Insider Buying and Selling

In other news, Director Margaret Pax acquired 250 shares of the company’s stock in a transaction that occurred on Monday, March 17th. The stock was purchased at an average cost of $150.69 per share, with a total value of $37,672.50. Following the purchase, the director now directly owns 1,043 shares of the company’s stock, valued at approximately $157,169.67. This trade represents a 31.53 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. 1.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in RGEN. Ballentine Partners LLC lifted its stake in shares of Repligen by 4.0% in the 4th quarter. Ballentine Partners LLC now owns 1,879 shares of the biotechnology company’s stock valued at $270,000 after purchasing an additional 72 shares in the last quarter. CIBC Asset Management Inc lifted its position in Repligen by 5.0% during the fourth quarter. CIBC Asset Management Inc now owns 1,706 shares of the biotechnology company’s stock valued at $246,000 after buying an additional 81 shares in the last quarter. GAMMA Investing LLC grew its stake in Repligen by 15.2% during the fourth quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company’s stock worth $98,000 after buying an additional 90 shares during the period. Louisiana State Employees Retirement System raised its stake in shares of Repligen by 0.7% in the 4th quarter. Louisiana State Employees Retirement System now owns 14,500 shares of the biotechnology company’s stock valued at $2,087,000 after acquiring an additional 100 shares during the period. Finally, Utah Retirement Systems lifted its holdings in shares of Repligen by 1.1% during the 4th quarter. Utah Retirement Systems now owns 9,294 shares of the biotechnology company’s stock valued at $1,338,000 after acquiring an additional 100 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.